WO2019127962A1 – July 4, 2019 – DRUG INSPECTION METHOD AND APPARATUS

Please complete the required fields.




Inventors :

TAN, Yidong - Room 1, No.2 Building, Huabei Mechatronic City, West Side, Rongli Road, Rongcheng County, Baoding, Hebei 071700; PAN, Yi - Room 1, No.2 Building, Huabei Mechatronic City, West Side, Rongli Road, Rongcheng County, Baoding, Hebei 071700; DING, Qing - Room 1, No.2 Building, Huabei Mechatronic City, West Side, Rongli Road, Rongcheng County, Baoding, Hebei 071700

Owner :

???????????? XIONGAN CHINA COMMUNICATION TECHNOLOGY CO., LTD. ????????????? SHENZHEN INSTITUTE OF TERAHERTZ TECHNOLOGY AND INNOVATION

Application Number :

WOCN18081324

Document Number :

WO2019127962A1

Priority Date :

December 30, 2017

Filing Date :

March 30, 2018

Date of Grant/ Publication :

July 4, 2019

Class :

G01N21 / 3581

Abstract

A drug inspection method and apparatus. The method comprises: emitting electromagnetic waves in a terahertz frequency band towards a sample to be inspected, the electromagnetic waves in the terahertz frequency band being probe waves; obtaining the inspection absorption spectrum of the probe waves for said sample; and determining, according to a preset reference absorption spectrum and the inspection absorption spectrum, whether said sample is a type of drug corresponding to the reference absorption spectrum. The present drug inspection method and apparatus can detect the type of a drug tested by means of analyzing the inspection absorption spectrum of the sample inspected after exposure to electromagnetic waves in a terahertz frequency band. The detection is swift and convenient.

Claim(s)

A method, comprising: administering a drug to a patient in, or in need thereof. A terahertz frequency band electromagnetic wave is emitted to a sample to be detected; wherein, the electromagnetic wave in the terahertz frequency band is a probe wave; and the electromagnetic wave is a detection wave. The detection absorption spectrum; and the detection absorption spectrum of the sample to be detected is acquired. To the preset reference absorption spectrum and the detection absorption spectrum, the sample to be detected is judged not to be the drug category corresponding to the reference absorption spectrum.;
The method, as recited 1, wherein the step of acquiring the detected absorption spectrum of the sample to be measured comprises: obtaining the detected absorption spectrum of the probe wave. The electromagnetic wave transmitted by the sample to be measured is received, and the electromagnetic wave is an attenuation wave; and the electromagnetic wave is an attenuation wave. To the spectrum of the attenuation wave and the spectrum, the detection absorption spectrum.;
The method, according to claim 1, wherein the detection absorption spectrum is a time domain terahertz spectrum; and the preset reference absorption spectrum is a frequency domain reference absorption spectrum; and the preset reference absorption spectrum is a frequency domain reference absorption spectrum. After the step of acquiring the detection absorption spectrum of the sample to be detected, the method comprises: after the step of obtaining the detection absorption spectrum of the detection wave. The detection absorption spectrum is subjected to Fourier transform, and the frequency domain detection absorption spectrum; and the frequency domain detection absorption spectrum is obtained. The method for determining whether the sample to be tested corresponds to the reference absorption spectrum according to the preset reference absorption spectrum and the detection absorption spectrum comprises: determining the type of the drug corresponding to the reference absorption spectrum. Whether the sample to be measured is the medicine category corresponding to the reference absorption spectrum is judged according to the frequency domain reference absorption spectrum and the frequency domain detection absorption spectrum.;
The method, according to claim 3, wherein the step of Fourier-transforming the detected absorption spectrum, and obtaining the frequency-domain-detected absorption spectrum comprises: after the step of obtaining the frequency-domain-detected absorption spectrum. The characteristic absorption frequency and absorption coefficient of the sample to be measured are acquired from the frequency domain detection absorption spectrum. The method for determining whether the sample to be tested corresponds to the reference absorption spectrum according to the preset reference absorption spectrum and the detection absorption spectrum comprises: determining the type of the drug corresponding to the reference absorption spectrum. The characteristic absorption frequency of the sample to be measured and the corresponding characteristic absorption frequency in the frequency domain reference absorption spectrum are compared, and the absorption coefficient of the sample to be detected and the absorption coefficient of the frequency domain reference absorption spectrum are compared; and the absorption coefficient corresponding to the frequency domain reference absorption spectrum is compared. When the characteristic absorption frequency of the sample to be measured corresponds to the characteristic absorption frequency corresponding to the frequency domain reference absorption spectrum, the sample to be detected is judged not to be the drug category according to the absorption rate of the sample to be detected and the absorption coefficient corresponding to the frequency domain reference absorption spectrum.;
The method, according to claim 4, wherein when the characteristic absorption frequency of the sample to be measured corresponds to a characteristic absorption frequency corresponding to the frequency domain reference absorption spectrum, the step of determining whether the sample to be detected is not the drug category comprises: determining whether the sample to be tested corresponds to the frequency domain reference absorption spectrum. The ratio; the absorption rate of the standard sample and the absorption rate of the sample to be measured is calculated. The ratio is compared with a preset range, and when the ratio is within the preset range, the sample to be detected is judged to be the medicine.;
The method, according to claim 1, wherein the detection of the sample to be measured is carried out in a nitrogen gas environment.;
The method, as recited 1, wherein the standard sample comprises at least one of hydantoin, dextromethamphetamine, ketamine hydrochloride, methylcarbazone hydrochloride, pseudoephedrine hydrochloride, ephedrine hydrochloride, cocaine base, caffeine, methylenedioxypyrrole-pentanone and synthetic cannabinoid components.;
A drug detection device, comprising: a device, and wherein, the device is configured to detect a drug. The sample platform, is used for supporting the sample; the sample platform is used for supporting the sample to be tested. The electromagnetic generator is used for transmitting electromagnetic waves of a terahertz frequency range to a sample to be detected; wherein the electromagnetic waves in the terahertz frequency band are detection waves; and the electromagnetic wave generator, the electromagnetic wave generator and the electromagnetic generator. The spectrum detector is used for obtaining the detection absorption spectrum of the sample to be detected on the detection wave. A processor, which is connected, is connected with the spectral tester, and the processor is used for judging whether the sample to be detected is of a medicine type corresponding to the reference absorption spectrum according to a preset reference absorption spectrum and the detection absorption spectrum.;
The apparatus, as recited 8, wherein the spectrum detector comprises an electromagnetic wave transmitted by the sample to be measured, the electromagnetic wave is an attenuation wave, and the detection absorption spectrum of the sample to be detected is obtained according to the spectrum of the attenuation wave and the spectrum, of the probe wave.;
The device, as recited 8, wherein the detection absorption spectrum is a time domain terahertz spectrum; the preset reference absorption spectrum is a frequency domain reference absorption spectrum; the processor performs Fourier transform, obtains a frequency domain detection absorption spectrum; and the processor determines whether the sample to be detected is a medicine category corresponding to the reference absorption spectrum according to the frequency domain reference absorption spectrum and the frequency domain detection absorption spectrum.

Summary

No Comments

Leave a comment

Sorry, you must be logged in to post a comment. Login